Accuray Incorporated

Accuray Incorporated

ARAYNYSE / NASDAQHealthcareSmall cap

$2.08-$0.04 (-1.9%)

Last close · Data as of Nov 20, 2026

Market cap
$43.5M
P/E
-27.3x
EV / EBITDA
8.0x
Revenue
$458.5M
Net margin
-0.3%
ROCE
2.8%

This period includes a one-day price step on 3 Nov 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Accuray Incorporated price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
Hidden
3M
Hidden
6M
Hidden
1Y
Hidden
5Y
Hidden
  • This period includes a one-day price step on 3 Nov 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

This period includes a one-day price step on 3 Nov 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Day change -$0.04 (-1.9%) from $2.12 to $2.08 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in ARAY, bought on each weekday since 2021.

News & filings

What Accuray Incorporated filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 1.6 million US dollars in fiscal 2025.

Strengths (1)

  • EBITDA grew 254.5% in fiscal 2025, 251.8 points more than revenue.
  • This period includes a one-day price step on 3 Nov 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China.

Read moreShow less

Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, the company offers post-contract customer support, installation, training, and other professional services. It primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.

Sector
Healthcare
Shares outstanding
112.6M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$43.5M
P/E
-27.3x
P/B
0.5x
EV / EBITDA
8.0x
EV / Sales
0.4x
P/S
0.1x
52-week high
Hidden
52-week low
Hidden

Profitability

Operating margin
1.7%
Net margin
-0.3%
EBITDA margin
4.4%
ROE
-2.0%
ROCE
2.8%
ROIC
4.6%
ROA
-0.3%
Asset turnover
0.98

Growth

Revenue
$458.5M
Revenue growth, 1Y
2.7%
Revenue CAGR, 3Y
2.2%
Net profit growth, 1Y
-89.8%
Free cash flow
-$5.7M

Solvency

Current ratio
1.65
Debt / Equity
2.17
Debt / Assets
0.38
CFO / Net profit
-1.80
Cash / Market cap
132.0%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$458.5M
Cost of revenue$311.5M
Gross profit$147.0M
Operating expenses$139.1M
Research and development$47.9M
Selling, general and administrative$91.2M
Operating income$7.8M
Interest and other-$6.7M
Pretax income$1.1M
Tax and other$2.7M
Net income-$1.6M

Revenue and net profit

Revenue grew 2.7% in FY2025; net profit is the dashed line.

Accuray Incorporated revenue and net profit by fiscal year
Accuray Incorporated revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$429.9M-$5.3M
FY2023$447.6M-$9.3M
FY2024$446.6M-$15.5M
FY2025$458.5M-$1.6M

Cash flows

FY2025: $2.9M from operations, -$5.7M free after investment (dashed).

Accuray Incorporated operating and free cash flow by fiscal year
Accuray Incorporated operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$2.4M-$7.1M
FY2023$15.5M$2.9M
FY2024-$11.9M-$15.5M
FY2025$2.9M-$5.7M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$458.5M+2.7%1Y
EBITDA
$20.2M+254.5%1Y
Net profit
-$1.6M
Cash from operations
$2.9M
Free cash flow
-$5.7M
Revenue CAGR, 3Y
2.2%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$458.5M$20.2M-$1.6M-$5.7M-2.0%+2.7%-89.8%

Monthly returns

Month-by-month returns of ARAY across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$470.2M
Liabilities$389.1M
Equity$81.2M
Paid-in capital$602.2M
Retained earnings-$519.3M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; ARAY highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

No company in this group has a positive P/E.

EV / Sales, for the companies without earnings

  1. Accuray Incorporated (this company)0.4x

Not shown (no positive earnings and no EV / Sales): Actuate Therapeutics, Inc. Common stock, Tevogen Bio Holdings Inc., Tvardi Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Accuray IncorporatedARAYthis company$43.5M-27.3x0.5x-2.0%8.0x
DocGo Inc.DCGO$56.3M-0.3x0.4x-126.7%-0.5x
aTyr Pharma, Inc.ATYR$50.3M-0.7x0.7x-109.8%-0.7x
Myomo, Inc.MYO$49.8M-3.2x4.4x-136.6%-4.4x
Actuate Therapeutics, Inc. Common stockACTU$46.4M-2.1x5.9x-280.5%—
Gossamer Bio, Inc.GOSS$41.7M-0.2x-0.3x138.8%-1.3x
Tevogen Bio Holdings Inc.TVGN$41.3M-1.6x-2.4x154.2%-1.9x
INmune Bio Inc.INMB$35.9M-0.8x1.5x-195.3%-0.4x
Tvardi Therapeutics, Inc.TVRD$28.9M-1.6x1.4x-87.0%-0.3x
Peer median—-1.2x1.1x-118.2%-0.7x

Year-to-date ROI

ARAY since 1 January, against earlier years.

Historical volatility

ARAY's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Accuray Incorporated operating margin by fiscal year
Accuray Incorporated operating margin by fiscal year
DateOperating margin
FY20221.9%
FY20230.5%
FY20240.1%
FY20251.7%
LineFY2025
Cost of revenueCost Of Revenue$311.5M
Gross profitGross Profit$147.0M
Operating expensesOperating Expense$139.1M
Research and developmentResearch And Development$47.9M
Total expensesTotal Expenses$450.7M
Pretax incomePretax Income$1.1M

Learn while you research

Academy chapters picked for Accuray Incorporated and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Leverage RatiosDebt/Equity of 2.17 is elevated, understand what that means for solvency.6 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →